RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SpringWorks Therapeutics Stock

SpringWorks Therapeutics Net Income 2024

SpringWorks Therapeutics Net Income

-251.37 M USD

Ticker

SWTX

ISIN

US85205L1070

WKN

A2PRLN

In 2024, SpringWorks Therapeutics's profit amounted to -251.37 M USD, a -22.68% increase from the -325.1 M USD profit recorded in the previous year.

The SpringWorks Therapeutics Net Income history

YEARNET INCOME (undefined USD)
2028e-90.91
2027e374.23
2026e-113.38
2025e-162.42
2024e-251.37
2023-325.1
2022-277.42
2021-173.91
2020-45.57
2019-50.58
2018-17.81
2017-4.64

SpringWorks Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into SpringWorks Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by SpringWorks Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects SpringWorks Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of SpringWorks Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into SpringWorks Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing SpringWorks Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on SpringWorks Therapeutics’s growth potential.

SpringWorks Therapeutics Revenue, EBIT and net profit per share

DateSpringWorks Therapeutics RevenueSpringWorks Therapeutics EBITSpringWorks Therapeutics Net Income
2028e2.05 B undefined-112.51 M undefined-90.91 M undefined
2027e1.2 B undefined166.94 M undefined374.23 M undefined
2026e531.1 M undefined-152.32 M undefined-113.38 M undefined
2025e388.27 M undefined-261.72 M undefined-162.42 M undefined
2024e198.51 M undefined-349.69 M undefined-251.37 M undefined
20235.45 M undefined-343.01 M undefined-325.1 M undefined
20220 undefined-280.67 M undefined-277.42 M undefined
20210 undefined-173.47 M undefined-173.91 M undefined
202035 M undefined-46.32 M undefined-45.57 M undefined
20190 undefined-59.24 M undefined-50.58 M undefined
20180 undefined-18.49 M undefined-17.81 M undefined
20170 undefined-4.66 M undefined-4.64 M undefined

SpringWorks Therapeutics stock margins

The SpringWorks Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SpringWorks Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SpringWorks Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the SpringWorks Therapeutics's sales revenue. A higher gross margin percentage indicates that the SpringWorks Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the SpringWorks Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the SpringWorks Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the SpringWorks Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the SpringWorks Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the SpringWorks Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

SpringWorks Therapeutics Margin History

SpringWorks Therapeutics Gross marginSpringWorks Therapeutics Profit marginSpringWorks Therapeutics EBIT marginSpringWorks Therapeutics Profit margin
2028e92.25 %-5.49 %-4.43 %
2027e92.25 %13.92 %31.21 %
2026e92.25 %-28.68 %-21.35 %
2025e92.25 %-67.41 %-41.83 %
2024e92.25 %-176.16 %-126.63 %
202392.25 %-6,297.28 %-5,968.5 %
202292.25 %0 %0 %
202192.25 %0 %0 %
202092.25 %-132.34 %-130.2 %
201992.25 %0 %0 %
201892.25 %0 %0 %
201792.25 %0 %0 %

SpringWorks Therapeutics Aktienanalyse

What does SpringWorks Therapeutics do?

SpringWorks Therapeutics Inc is a biopharmaceutical company focused on developing innovative drugs for rare and hard-to-treat diseases. The company was founded by Pfizer Inc. in 2017 and is headquartered in Stamford, Connecticut, USA. Since then, it has become one of the leading companies in the industry and works closely with scientists, doctors, and patients to develop better therapies for rare diseases. The business model of SpringWorks Therapeutics Inc is based on identifying and developing drugs for chronic and severe diseases with currently no satisfactory treatment options. The company places great emphasis on the use of new technologies and scientific knowledge to maximize the effectiveness and safety of its drugs. At the same time, it strives to advance product development as quickly and efficiently as possible in order to offer patients better treatment options as soon as possible. An important part of SpringWorks Therapeutics Inc's business model is partnerships and collaborations with other companies and institutions. The company works closely with other biopharmaceutical and biotechnology companies to accelerate its development plans and maximize the potential of its drugs. It also maintains close relationships with research institutes, such as the National Institutes of Health (NIH), to gain the latest scientific knowledge and translate it into new therapies. SpringWorks Therapeutics Inc specializes in the development of drugs for rare and hard-to-treat diseases. The company focuses on four main areas: oncology, neurology, hematology, and pediatrics. In each of these areas, the company has a number of promising programs and products in development. In the oncology field, SpringWorks Therapeutics Inc focuses on developing therapies for patients with rare and hard-to-treat types of cancer. An important program in this area is the development program for Nirogacestat, a gamma-secretase inhibitor. This program has the potential to provide a new treatment option for patients with T-cell lymphoblastic lymphoma (T-ALL) and Alport syndrome. In the neurology field, SpringWorks Therapeutics Inc develops therapies for patients with rare neurological diseases that currently have no satisfactory treatment options. An important focus in this area is the development program for Mirdametinib, a MEK1/2 inhibitor. This program has the potential to offer a new treatment for patients with neurofibromatosis type 1 (NF1). In the hematology field, SpringWorks Therapeutics Inc focuses on developing therapies for patients with rare hematological diseases such as myelofibrosis, chronic myeloid leukemia (CML), and acute myeloid leukemia (AML). An important focus in this area is the development program for Senexin A, an inhibitor of protein methyltransferases. This program has the potential to provide a new therapy for patients with myelofibrosis. In the pediatrics field, SpringWorks Therapeutics Inc develops therapies for children with rare and severe diseases such as nephrotic syndrome and epilepsy. An important program in this area is the development program for PD-0325901, a MEK1/2 inhibitor. This program has the potential to offer a new treatment for patients with nephrotic syndrome. Overall, SpringWorks Therapeutics Inc has an impressive pipeline of promising development programs that have the potential to improve the lives of patients with rare and hard-to-treat diseases. Through its close collaboration with other companies, research institutes, and patient organizations, the company is able to effectively and efficiently implement its development plans and thus create better treatment options for patients around the world. SpringWorks Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding SpringWorks Therapeutics's Profit Margins

The profit margins of SpringWorks Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of SpringWorks Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating SpringWorks Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

SpringWorks Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When SpringWorks Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about SpringWorks Therapeutics stock

How much profit has SpringWorks Therapeutics made this year?

SpringWorks Therapeutics has made -251.37 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -22.68% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does SpringWorks Therapeutics publish its earnings?

SpringWorks Therapeutics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of SpringWorks Therapeutics?

The profits of SpringWorks Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of SpringWorks Therapeutics?

You can learn more about the earnings of SpringWorks Therapeutics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does SpringWorks Therapeutics pay?

Over the past 12 months, SpringWorks Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SpringWorks Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of SpringWorks Therapeutics?

The current dividend yield of SpringWorks Therapeutics is .

When does SpringWorks Therapeutics pay dividends?

SpringWorks Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SpringWorks Therapeutics?

SpringWorks Therapeutics paid dividends every year for the past 0 years.

What is the dividend of SpringWorks Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is SpringWorks Therapeutics located?

SpringWorks Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von SpringWorks Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SpringWorks Therapeutics from 9/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/7/2024.

When did SpringWorks Therapeutics pay the last dividend?

The last dividend was paid out on 9/7/2024.

What was the dividend of SpringWorks Therapeutics in the year 2023?

In the year 2023, SpringWorks Therapeutics distributed 0 USD as dividends.

In which currency does SpringWorks Therapeutics pay out the dividend?

The dividends of SpringWorks Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SpringWorks Therapeutics

Our stock analysis for SpringWorks Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SpringWorks Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.